Chardan Capital Has Lowered Expectations for Krystal Biotech (NASDAQ:KRYS) Stock Price

Key Points

• Chardan Capital has reduced its price target for Krystal Biotech (NASDAQ:KRYS) from $219.00 to $216.00, maintaining a "buy" rating which indicates a potential upside of 48.25% from the recent closing price.
• Analysts' price targets for Krystal Biotech vary, with other firms like Guggenheim and Citigroup also lowering their targets, highlighting a consensus target price of $210.38 across multiple ratings.
• Insider selling and significant increases in institutional holdings over recent quarters show active trading trends in Krystal Biotech's stock ownership landscape.

Krystal Biotech (NASDAQ:KRYS - Free Report) had its price target trimmed by Chardan Capital from $219.00 to $216.00 in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also recently commented on KRYS. HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Friday, August 22nd. Bank of America lowered their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Guggenheim decreased their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Citigroup reiterated a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $210.38.

Krystal Biotech Stock Down 0.1%

Shares of NASDAQ KRYS traded down $0.15 during midday trading on Friday, reaching $146.73. 43,574 shares of the company's stock traded hands, compared to its average volume of 328,581. The stock's 50 day simple moving average is $144.84 and its 200-day simple moving average is $154.39. The company has a market cap of $4.25 billion, a price-to-earnings ratio of 29.81 and a beta of 0.70. Krystal Biotech has a one year low of $122.80 and a one year high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Equities analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares in the company, valued at $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 over the last 90 days. Company insiders own 13.70% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds have recently made changes to their positions in KRYS. Thrivent Financial for Lutherans raised its stake in Krystal Biotech by 0.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 18,700 shares of the company's stock valued at $2,571,000 after purchasing an additional 110 shares during the period. Public Sector Pension Investment Board lifted its stake in shares of Krystal Biotech by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 86,688 shares of the company's stock valued at $11,916,000 after buying an additional 6,424 shares during the period. Tower Research Capital LLC TRC raised its position in Krystal Biotech by 310.7% in the second quarter. Tower Research Capital LLC TRC now owns 2,998 shares of the company's stock worth $412,000 after purchasing an additional 2,268 shares in the last quarter. E Fund Management Co. Ltd. raised its position in Krystal Biotech by 71.4% in the second quarter. E Fund Management Co. Ltd. now owns 3,870 shares of the company's stock worth $532,000 after purchasing an additional 1,612 shares in the last quarter. Finally, Soleus Capital Management L.P. increased its holdings in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock worth $126,870,000 after buying an additional 481,200 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).